Advisory Boards

Patient Resource has assembled a prestigious Advisory Board to assist with editorial focus and ensure accuracy of the information presented. Members include well-known names from business and industry, opinion leaders from non-profit organizations, and highly respected medical doctors from the nation’s leading cancer treatment facilities. Editor-in-Chief is Charles M. Balch, MD, FACS, who oversees a team of seasoned medical writers to ensure editorial content is both accurate and engaging and presented with a sensitive professionalism meant to empower cancer patients and their families.


Dr. Balch's Award Video

Dr. Charles Balch was previously honored with the Gold T Award in recognition of outstanding achievement in his field by The University of Toledo.
View his featured award video here.




Editor-in-Chief:

  

Charles M. Balch, MD, FACS

Professor of Surgery, The University of Texas MD Anderson Cancer Center
Editor-in-Chief, Patient Resource LLC
Editor-in-Chief, Annals of Surgical Oncology
Past President, Society of Surgical Oncology



Click to Read More

Dr. Charles M. Balch, oncologist, surgeon, and one of the world’s preeminent melanoma and breast cancer experts, has devoted more than 40 years to trailblazing research and to leadership positions in academic and clinical settings. Dr. Balch is a renowned teacher and lecturer and a revered mentor in the field of surgery and oncology. He currently serves as professor of surgery at the University of Texas MD Anderson Cancer Center in Houston and as editor-in-chief of Patient Resource Cancer Guides.

Dr. Balch has led global efforts to build networks in the areas of outcomes research and clinical trials, authoring more than 750 publications on clinical investigations involving staging and prognostic factors in melanoma, standards of surgical treatment in melanoma and breast cancer, and the conduct and methodology of clinical research and immunology. His laboratory research accomplishments include significant contributions in tumor immunology and human T lymphocyte differentiation. His scientific publications have been cited in the biomedical literature in more than 23,000 articles, and he has lectured in more than 42 countries and most major U.S. academic centers.

Dr. Balch previously chaired the Melanoma Staging Committee of the American Joint Committee on Cancer (AJCC). He is editor of Cutaneous Melanoma, the authoritative textbook on melanoma, now in its fifth edition. He is the founding editor-in-chief of the Annals of SurgicalOncology and Breast Diseases (emeritus).

Dr. Balch most recently served at the University of Texas Southwestern Medical Center in Dallas as professor of surgery and before that at Johns Hopkins Medical Center as professor of surgery, oncology and dermatology; deputy director for clinical trials and outcomes research; and director of the Johns Hopkins Clinical Research Network. He earlier fulfilled similar duties at UT M. D. Anderson Cancer Center, The City of Hope National Medical Center, and the University of Alabama at Birmingham.

As Melanoma Staging Committee chair, Dr. Balch and other experts organized the largest prognostics factors analysis ever conducted. The study involved 60,000 melanoma patients from three continents and major cancer cooperative groups. Their analyses extensively revised the staging system for melanoma. Dr. Balch’s contributions to the melanoma literature comprise six books and nearly 200 book chapters and articles relating to his clinical investigations. He has been a principal investigator of numerous clinical trials, many of them NCI-funded National Phase III trials, and has assumed key roles internationally in randomized surgical trials. The results of these trials have defined current melanoma surgery standards and established the safety of using more conservative surgical excision of primary melanoma. Additionally, he has led five cooperative clinical trials involving combinations of adjuvant biological therapy or chemotherapy in high-risk melanoma patients.

In the area of breast cancer, Dr. Balch was a co-principal investigator in the only randomized surgical trial comparing Halsted radical mastectomy with modified radical mastectomy. He helped pioneer skin saving mastectomies followed by immediate breast reconstruction. His immunology research has included participation in fundamental work delineating human T lymphocyte and NK cell differentiating surface markers, and in developing the anti-HNK1 monoclonal antibody that fi rst identifi ed the CD57 antigen on NK cells. Dr. Balch has served in various administrative and leadership positions with the American Society of Surgical Oncology (president), the American Board of Surgery (board of directors), the Association of Academic Surgeons (president), the Commission on Cancer (chair, board of directors), and the AJCC (executive committee). Recent honors include an honorary PhD from the University of Crete and the Highest Alumni Award from the University of Toledo, where he graduated with a BS in biology. He earned his MD from Columbia University College of Physicians and Surgeons.


U.S. Medical Advisory Board Members:




James O. Armitage, MD

The Joe Shapiro Professor of Medicine, Division of Oncology/Hematology,
University of Nebraska Medical Center
Past President, American Society of Clinical Oncology
Past President, American Society for Blood and Marrow Transplantation



Click to Read More

Dr. James O. Armitage is a graduate of the University of Nebraska Medical Center, completed his internship and residency in internal medicine at Nebraska, a fellowship in hematology oncology at the University of Iowa and a brief stint in private practice in Omaha. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. He served as Vice-Chair of Internal Medicine, Chair of Internal Medicine, Dean of the College of Medicine and currently is The Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center. Dr. Armitage is board certified in internal medicine, medical oncology and hematology, a Fellow of both the American and Royal College of Physicians, a past member of the National Cancer Advisory Board, past president of the American Society of Clinical Oncology and American Society for Blood and Marrow Transplantation. He is married and the father of four children and four grandchildren.


Marty A. Makary, MD, MPH, FACS

Chief, Minimally-Invasive Surgical Oncology, Johns Hopkins Hospital
Professor of Surgery and Health Policy, Johns Hopkins University School of Medicine



Click to Read More

Dr. Makary specializes in minimally-invasive cancer surgery and is professor of surgery and health policy at Johns Hopkins University. Dr. Makary is an active researcher, focusing on the delivery of health care and public health implications of new medical interventions. He is a frequent medical commentator for CNN and Fox News, and speaks nationally on the subjects of healthcare quality, health policy and cancer prevention.

Dr. Makary led The United Nations World Health Organization (W.H.O.) technical work group to develop standardized health metrics to compare surgical outcomes across countries. From his overseas experiences, Dr. Makary founded The Lotus Global Health Foundation®, a non-profit organization which supports humanitarian medical efforts in developing countries.

Dr. Makary is the recipient of numerous research and teaching awards, including the Research Award of the Washington Academy of Surgery and the Best Teacher Award for Georgetown Medical School.

He is the author of “General Surgery Review”, a textbook of surgery, and over 100 scientific publications. His research expertise includes high-risk populations, environmental health, and risk management in medicine. He is internationally recognized for outcomes research and his work has been published in The New England Journal of Medicine and The New York Times.

In 2007, he was named the Mark Ravitch Endowed Chair in Gastrointestinal Surgery, becoming the youngest surgeon at Johns Hopkins to receive an endowed chair.

Dr. Makary holds degrees from Harvard University, Thomas Jefferson University, and Bucknell University. He completed surgical training at Johns Hopkins University and Georgetown University.


J. Max Austin Jr., MD

Professor Emeritus of Gynecologic Oncology, Department of Obstetrics and Gynecology, UAB Medical Center
Past President, Society of Gynecologic Oncologists



Click to Read More

As a young man, J. Max Austin, Jr., M.D. left his home town of Wetumpka, Alabama to attend Georgia’s Emory University. Four years and a bachelor’s degree later he came back to his home state, earning a medical degree at the Medical College of Alabama in 1967. Except for a year out of the state for residency training and two years in the Air Force, Austin has been in Alabama ever since.

Dr. Austin has practiced gynecologic oncology and taught residents and fellowship students in this state throughout his career. Indeed, the state of Alabama-and treating its female cancer patients-are very dear to his heart.

Dr. Austin did his first year of residency in Atlanta in 1968-69, then he finished his OB/GYN residency and fellowship in Alabama. Having progressed along the academic ladder, he is now a full professor at the UASOM. He also founded Southern Gynecology, a private practice in Birmingham, and practiced there 22 years.

When Dr. Austin returned to the UASOM in 2000, the University of Alabama Health Services Foundation and the Department of Obstetrics and Gynecology established the J. Max Austin, Jr., M.D. Endowed Chair in Gynecologic Oncology in honor of his contributions to medicine and medical education in Alabama.

“There are some counties in Alabama that are equivalent to third-world countries in the death rates from cervical cancer, “he says. “This is tragic. We need to continue to educate, to teach the latest techniques in detection and diagnosis of gynecologic malignancies because many of them are potentially treatable if diagnosed early.”


Lisa A. Newman, MD, MPH, FACS, FASCO

Director, Breast Oncology Program, Henry Ford Health System



Click to Read More

Dr. Lisa A. Newman is a breast cancer surgeon, and serves as director of the Breast Oncology Center and International Center for the Study of Breast Cancer Subtypes at Henry Ford Health System. She received her medical degree from the State University of New York Health Science Center at Brooklyn. Dr. Newman completed her fellowship in surgical oncology at the M.D. Anderson Cancer Center and received her Masters Degree in Public Health from Harvard University.

She is internationally known for her research on ethnicity-related variation in breast cancer risk, including the biologic and genetic origins of triple negative breast cancer which is the focus of her ongoing work in Ghana.

In addition to leading a team at the forefront of breast cancer research and treatment at Henry Ford, she is the Chief National Medical Advisor for the Sisters Network Inc., and actively promotes collaborative breast cancer research through roles at the University of Texas M.D. Anderson Cancer Center and University of Michigan School of Public Health.

She holds leadership positions in the most prominent of cancer academic and advocacy organizations including the American College of Surgeons and the American Cancer Society, most recently receiving the distinction of Komen Scholar.


Al B. Benson III, MD, FACP, FASCO

Professor of Medicine, Associate Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Past President, Association of Community Cancer Centers



Click to Read More

Al B. Benson III, MD, is a professor of medicine in the Division of Hematology/Oncology at Northwestern University’s Feinberg School of Medicine in Chicago. He is also the associate director for cooperative groups at the Robert H. Lurie Comprehensive Cancer Center, a National Cancer Institute-designated comprehensive cancer center, at Northwestern University. In addition, he is an attending physician at Northwestern Memorial Hospital, a staff physician at Jesse Brown VA Medical Center, and a consultant to the Rehabilitation Institute of Chicago.

Dr. Benson earned his medical degree at the University at Buffalo, The State University of New York, following which he completed an internal medicine residency at the University of Wisconsin Hospital and Clinics in Madison, Wis. He was an assistant professor of medicine at the University of Illinois and co-medical director for the National Public Health Service in Champaign, Ill. He then served as a clinical oncology and research fellow at the University of Wisconsin Clinical Cancer Center, where he received an American Cancer Society Fellowship Award.

Dr. Benson is active on numerous professional committees, often serving as an officer. He is a recipient of the American Society of Clinical Oncology (ASCO) Statesman Award (Fellow of ASCO) and has served on a number of committees. He has been a member of the Task Force on Quality of Cancer Care, the co-chair of ASCO’s Colorectal Cancer Guidelines Subcommittee, the Stage II Colon Cancer Guidelines Panel and the Guidelines Panel for Use of Radiofrequency Ablation for Colorectal Cancer Hepatic Metastases. He also is the chair of both the Eastern Cooperative Oncology Group Gastrointestinal and Data Monitoring Committees and a member of the NCI GI Steering Committee. In addition, he is a past president of the Illinois Medical Oncology Society, past president of the Association of Community Cancer Centers (ACCC), an executive committee member and immediate past-chair of the Board of Directors of the National Comprehensive Cancer Network (NCCN) and a member of the Board of Directors of the NCCN Foundation. He is the chair of both the NCCN Hepatobiliary Guidelines Panel and of the Colon, Rectal and Anal Panel, and a member of the Pancreatic Cancer and Neuroendocrine Panels. He is also a past president of the International Society of GI Oncology (ISGIO). Dr. Benson is a member of the Scientific Board of Directors of the Patient Advocate Foundation, the National Patient Advocate Foundation and Friends of Cancer Research.

He is on the editorial board of the ASCO Connection, American Health and Drug Benefits, Personalized Medicine in Oncology, Journal of Comparative Effectiveness Research and Gastrointestinal Cancer Research, among others.

His most recent national awards include the NCCN Rodger J. Winn award and the ACCC Outstanding Achievement in Clinical Research Award.

Dr. Benson’s research is primarily in the areas of gastrointestinal cancer clinical trials, cancer clinical trials, biologic therapies, phase I cancer clinical trials and cancer guideline development. He has authored or co-authored numerous reports, reviews and book chapters focusing on these topics. His research in biologics, cancer therapy and cancer prevention has been awarded funding from a variety of sources including the NIH.


John E. Niederhuber, MD

Executive Vice President, Inova Health System
CEO, Inova Translational Medicine Institute
Deputy Director, Johns Hopkins Clinical Research Network
Former Director, University of Wisconsin Comprehensive Cancer Center
Past President, Society of Surgical Oncology
Past President, Association of American Cancer Institutes



Click to Read More

Dr. John Niederhuber is a nationally renowned surgeon and researcher with a clinical emphasis on gastrointestingal, hepatobiliary and breast cancers. He is recognized for his pioneering work in hepatic artery infusion chemotherapy. Dr. Niederhuber has been a long-time external advisor to the National Cancer Institute and has authored and coauthored more than 180 publications and edited four books.

Dr. Niederhuber recently joined Inova Health System as Executive Vice President and CEO of the Inova Translational Medical Institute. Prior to that, he served as Director of the National Cancer Institute, one of the National Institutes of Health from 2006 until July, 2010. During his tenure as NCI director, Dr. Niederhuber shaped the Nation’s investment in cancer to address areas that are likely to pay the largest health dividends. He began The Cancer Genome Atlas, an effort to comprehensively identify the genomic changes in all major cancer types and subtypes. In addition to genomic studies of cancer and work in cancer immunotherapy, programs in nanobiology, systems biology, investigations into the tumor microenvironment, cancer initiating cells, and subcellular imaging have benefited under his direction. Dr. Niederhuber is recognized by his peers as a visionary leader in oncology. He daily puts into practice his expertise as both a cancer physician and a basic research scientist. His colleagues have acknowledged his leadership and accomplishments by electing him vice president and president of the Society for Surgical Oncology and president of the Association of American Cancer Institutes. He has served as a member of C-Change (a community of executives from government, business and non-profit communities dedicated to conquering cancer) and as a member of the CEO Roundtable on Cancer. Dr. Niederhuber is a member of the Institute of Medicine of the National Academy of Sciences, recognizing his outstanding scientific accomplishments and commitment to service in health sciences.


Thomas A. Buchholz, MD, FACR

Executive Vice President and Physician-in-Chief, The University of Texas MD Anderson Cancer Center



Click to Read More

Dr. Buchholz is executive vice president and physician-in-chief at The University of Texas MD Anderson Cancer Center, Houston where he holds the Frank T. McGraw Memorial Chair in the Study of Cancer. Dr. Buchholz received his MD degree from Tufts University School of Medicine in Boston, MA and his postdoctoral residency and fellowship training at the University of Washington School of Medicine in Seattle, WA. His major clinical and research interest has been in the field of breast cancer radiation oncology.


Nicholas J. Petrelli, MD

Bank of America Endowed Medical Director, Helen F. Graham Cancer Center and Research Institute
Professor of Surgery, Thomas Jefferson University
Past President, Society of Surgical Oncology
Past Chair, Colorectal Committee of the National Surgical Adjuvant Breast and Bowel Project (NSABP)



Click to Read More

Dr. Nicholas Petrelli is a Professor of Surgery in the Department of Surgery at Thomas Jefferson University and the Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center and Research Institute at Christiana Care Health Systems, Newark, Delaware.

Dr. Petrelli has been active on numerous advisory panels, including the American Society of Clinical Oncology Expert Panel on Colorectal Cancer Surveillance and the National Cancer Institute Colorectal Cancer Consensus Working Group. He is a member of a number of professional organizations, including the Society of University Surgeons, the American Surgical Association, the American Society of Clinical Oncology, and the Society of Surgical Oncology. He is the past President of the Society of Surgical Oncology and past chair of the Colorectal Committee of the National Surgical Adjuvant Breast and Bowel Project (NSABP).

Dr. Petrelli has authored 335 manuscripts in peer reviewed journals and is the editor of the Surgical Oncology Clinics of North America. He is an associate editor for the Annals of Surgical Oncology and a co-editor of Surgical Oncology.

Dr. Petrelli earned his undergraduate degree from the University of Notre Dame in 1969 and his medical degree from Tulane Medical School in 1973. He completed his general surgery residency in San Francisco in 1978 and post doctoral training in surgical oncology at the Roswell Park Cancer Institute in 1980. He spent the ensuing 21 years at the Roswell Park Cancer Institute during which time he was appointed Chair of the Division of Surgical Oncology and Director of the Surgical Oncology Fellowship Program from 1991 to 2001.

He has been married to his wife Cathy for 38 years and they have two children, Nicole and Gabriella. Nicole has degrees in criminal justice and forensic science and Gabriella in psychology. Dr Petrelli continues to enjoy Delaware beach time with his family and the rich history of the Delaware Valley. He has family in the New York City area, making it convenient for spur of the moment visits. He also has two nephews, Doug and Justin, who keep him young at heart with visits to Midtown Manhattan.


Paul A. Bunn, MD, FASCO

Distinguished Professor and James Dudley Endowed Professor of Lung Cancer Research, University of Colorado School of Medicine
Past President, American Society of Clinical Oncology
Past President and Past CEO, International Association for the Study of Lung Cancer



Click to Read More

Education

Amherst College – 1967
Cornell University Medical Center
New York, NY – 1971

Bio

In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986, Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center. Dr. Bunn has been President of ASCO, IASLC, and AACI, chairman of the FDA Oncology Drug Advisory Committee, and is currently the Executive Director of the IASLC.

Research

Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct translational research.

Publications

Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA, Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18(4), 752-60, 2007.

Frederick B., Helfrich B., Coldren C.,. Zheng D., Chan D., Bunn P.A., Jr, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small-cell lung cancer. Mol Cancer Ther 6:(6), 2007.

Funding

University of Colorado Cancer Center Support Grant: NIH/NCI 4/4/97-1/31/11. $2,832,858 - 45% effort. The major goals are to contribute, through a coordinated research, clinical treatment, control and education effort to the eventual elimination of cancer as a human health problem and provide the citizens of the State of Colorado and the Rocky Mountain Region with state-of-the-art cancer therapy, research, control and education programs.

SPORE In Lung Cancer: NIH/NCI 09/30/1992 to 04/30/2013. $1,600,999 - 25% effort combined
The major goal of the overall project is to establish a Specialized Program in Research Excellence (SPORE) in Lung Cancer to expand our understanding of the biology of lung cancer, to find new methods of diagnosis, prevention and treatment and to serve as a regional, national and international resource for the study of lung cancer.


Raphael E. Pollock, MD, PhD, FACS

Surgeon-in-Chief, James Comprehensive Cancer Center & The Ohio State University Health System
Kathleen Wellenreiter Klotz Chair in Cancer Research, Professor and Director, Division of Surgical Oncology, The Ohio State University Wexner Medical Center
Past President, Society of Surgical Oncology



Click to Read More

Dr. Raphael Pollock, MD, PhD was born in Chicago, IL where he received his primary and secondary school education. Dr. Pollock graduated from Oberlin College in 1972 with a BA in History (high honors). He received his MD degree from St. Louis University, St. Louis, Missouri and then completed residency training in General Surgery at the University of Chicago and Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL. This was followed by a fellowship in Surgical Oncology at the University of Texas MD Anderson Cancer Center, Houston, TX. Upon completion of fellowship training in 1984, Dr. Pollock joined the faculty in the Department of Surgical Oncology at The University of Texas. He completed PhD training at the Graduate School of the Biological Sciences, University of Texas Health Sciences Center / Houston in 1990, and was promoted to Associate Professor the following year. Dr. Pollock became Chairman of the Department of Surgical Oncology in 1993, was promoted to Professor in 1995, and became Head of the Division of Surgery at The University of Texas MD Anderson Cancer Center in 1997. He is currently surgeon-in-chief at the James Comprehensive Cancer Center and The Ohio State University Health System.

Dr. Pollock has a lifetime professional dedication to patient care and research in soft tissue sarcoma. His clinical practice focuses exclusively on this disease entity, and he has pursued clinical and laboratory research interests in soft tissue sarcoma during the entire time that he has been a member of the faculty of the Department of Surgical Oncology. Currently Dr. Pollock provides leadership for the Sarcoma Research Center at The University of Texas MD Anderson Cancer Center. His laboratory research interests include molecular-oriented tissue- and cell line-based investigations focusing on the role of the p53 tumor suppressor gene in soft tissue sarcoma, modulation of angiogenesis in soft tissue sarcoma, mechanisms of soft tissue sarcoma chemoresistance, as well as the development of novel therapeutics for this disease. Dr. Pollock was the incumbent in the Senator A.M. Aiken, Jr., Distinguished Chair, and held joint appointments in the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer and the Department of Surgery at The University of Texas Health Sciences Center/ Houston.


Michael A. Caligiuri, MD

Director, The Ohio State University Comprehensive Cancer Center
CEO, Arthur G. James Cancer Hospital & Richard J. Solove Research Institute
President, American Association for Cancer Research



Click to Read More

Michael A. Caligiuri, MD, is director of The Ohio State University Comprehensive Cancer Center, chief executive officer of Ohio State’s James Cancer Hospital and Solove Research Institute, and holder of the John L. Marakas Nationwide Insurance Enterprise Foundation Chair in Cancer Research. He also is a professor in the Department of Internal Medicine and the Department of Molecular Virology, Immunology and Medical Genetics in Ohio State’s College of Medicine. Dr. Caligiuri’s laboratory has evolved to investigate:

- Development and normal role of the body's large granular lymphocytes called natural killer cells so as to exploit their properties to develop effective therapies against cancer and immune deficiency;

- Why organ transplant patients with iatrogenic immune deficiency are highly susceptible to developing lymphoma associated with the Epstein-Barr virus, and to develop a preventive strategy for this disorder. His lab uses a SCID-human mouse model to explore therapies for treating this and other types of lymphoma;

- The molecular basis for the development of acute leukemia. His lab has mouse models of leukemia as well as the world's largest bank of human leukemia cells to study the pathogenesis of acute leukemia, the prognostic significance of molecular defects in acute leukemia, and novel therapies for acute leukemia.

Since 1990, more than 100 students have trained in the Caligiuri laboratory and have received numerous awards for their research. Dr. Caligiuri has designed and conducted many clinical studies for leukemia and lymphoma patients and has more than 400 original publications, abstracts and review articles on immunology or leukemia.

He also is an elected member of the American Society for Clinical Investigation and the Association of American Physicians, and he is an elected Fellow in the American Association for the Advancement of Science. In 2007, he was elected as vice president and president-elect of the Association for American Cancer Institutes (AACI), and he served as AACI president through 2011. He chairs the AACR Publications Committee and is a past editor of the journal Blood. Dr. Caligiuri has served on numerous national and international committees, including the National Cancer Institute (NCI) Board of Scientific Advisors; he either chairs or is a member of 12 cancer center advisory boards across the country. In 2010, Dr. Caligiuri was one of four individuals in the country to receive a MERIT award from the National Cancer Institute for his work on immunity and cancer.

Dr. Caligiuri earned his medical degree from Stanford University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital at Harvard Medical School in Boston, then completed a fellowship in medical oncology, bone marrow transplantation and immunology at the Dana-Farber Cancer Institute at Harvard Medical School. He next spent seven years at Roswell Park Cancer Institute as an assistant, associate and full professor before moving to The Ohio State University in 1997.


Richard B. Reiling, MD

Past President, Association of Community Cancer Centers



Click to Read More

Dr. Richard Reiling is a native of Dayton, Ohio and received his undergraduate education at the University of Dayton. In the interim between undergraduate studies and medical school, he was a high school teacher, the beginning of a life-long avocation for teaching. After graduating from Harvard Medical School he completed training in surgery at Harvard and an oncology Fellowship at the Lahey Clinic.. He served in the USAF during the Vietnam conflict era. Dr. Reiling entered private practice in his hometown at the same time that a new medical school was being formed in Dayton. He became a charter faculty member at Wright State University School of Medicine and remains on that faculty throughout his career. Currently, Richard is a Clinical Professor of Surgery at Wright State.

Dr Reiling’s personal interest has always been in the care of patients with cancer, especially those with breast cancer. He was instrumental in developing a cancer program at his main hospital, Kettering Medical Center, named after the inventor Charles F. Kettering and located on the lawns of the former Kettering estate. The hospital was shortly thereafter recognized by US News and World Report as one of the nation’s top 50 hospitals for cancer care. During this time he continued a very active practice as well as a busy teaching schedule.

In the summer of 2000, he was recruited by Ohio Health’s flagship hospitals in Columbus, Ohio as the VP for Cancer Services. During the next several years, Dr. Reiling provided the support and leadership to bring that institution’s cancer program to a high level of recognition in a community that already had a major cancer hospital as part of Ohio State University.

He found an offer to a similar position as the Medical Director of the Presbyterian Cancer Center too good to not accept. The position at Presbyterian and the beauty of the city was enough for the Reilings to give up their Ohio roots and move to the Carolinas.

Dr. Reiling has worked diligently to develop programs that improve the care of patients with cancer. In addition to breast cancer, he is especially active in lung cancer. It is in this situation that he has a very strong interest in the prevention of lung cancer and other respiratory diseases related to cigarette smoke. He has served with SmokeFree Mecklenburg for several years and often speaks and writes about the hazards of second-hand smoke.

Dr. Reiling has served on many professional society boards and committees, including the President of the Ohio Chapter of the American College of Surgeons and a Governor of the American College of Surgeons. Currently, he is the Second VP-Elect of the American College of Surgeons. In addition, he has served on many community and church organizations including the United Way, and the Dayton Opera Association. In his spare time, he was able to be a Boy Scout Master for a troop in Kettering Ohio, and proudly lists many young men who became Eagle Scouts during his tenure. Currently he serves on the Mecklenburg Council of the Boys Scouts of America, along with other civic boards. He is a member of the Charlotte Rotary Club.

Dr. Reiling is married to his childhood sweetheart, Liz, and celebrated their 44th anniversary this June. The Reilings have two grown children, Maureen DeBlois, a senior hospital executive in Atlanta, and Richard B. Reiling Jr., an attorney in Boston. The Reiling’s have 3 grandchildren. Richard enjoys golf, skiing, and just being involved.


Kaisorn L. Chaichana, MD

Assistant Professor of Neurosurgery, Oncology and Otolaryngology, Johns Hopkins University School of Medicine



Click to Read More

Dr. Kaisorn L. Chaichana is an Assistant Professor of Neurosurgery, Oncology and Otolaryngology and specialized in surgical neuro-oncology and skull base surgery at Johns Hopkins University School of Medicine. Chaichana is an active researcher in clinical outcomes and brain tumor stem cell research. He has published over 100 peer-revised papers in various prestigious journals.


William S. Rosenberg, MD

Neurosurgeon and Founder, Center for the Relief of Pain, Kansas City, Mo.
President Emeritus and Founder, Cancer Pain Research Consortium



Click to Read More

A California native, Dr. William S. Rosenberg attended Harvard Medical School in Boston, graduating in 1987. He completed his neurosurgical residency at Massachusetts General Hospital, also located in Boston, in 1993. He is a Fellow of the American Association of Neurological Surgery and a Diplomate of the American Board of Neurological Surgery.

Dr. Rosenberg began his career with the Mayfield Clinic in Cincinnati (1994 to 1998), where he was the Director of Neurotrauma and Neurocritical Care at the University of Cincinnati and specialized in complex spinal surgery. He was then recruited to co-direct the Neurospinal Disorders Program in the Department of Neurosurgery, University of California, San Francisco, from 1998 to 2002, where he co-founded the Spinal Biomechanics Laboratory at the University of California, Berkeley. Dr. Rosenberg left academic neurosurgery in 2002, joining Midwest Neurosurgery Associates in Kansas City, Mo., out of a desire for greater focus on patient care and the ability to spend more time with family.

In Kansas City, Dr. Rosenberg continued to pursue interests in complex spinal surgery. He brought CyberKnife Radiosurgery to the Kansas City area and served as medical director for the Menorah CyberKnife Center for its first six years. In addition, he expanded his area of expertise to include the treatment of chronic and cancer-related pain, founding and directing the Center for the Relief of Pain at Research Medical Center, where patient-centered, diagnosis-based pain care is emphasized. Perceiving an unmet need in cancer pain care, Dr. Rosenberg founded and is president emeritus of the Cancer Pain Research Consortium, a multidisciplinary group of experts from across North America dedicated to the generation and promotion of patient-centered, evidence-based care for cancer-related pain and suffering. Dr. Rosenberg is actively involved in treating patients with such modalities as neuromodulation, intrathecal pharmacotherapy, peripheral nerve, spinal cord and deep brain stimulation. He is also very active in training other health care providers, curriculum development and lecturing, as well as designing and supervising clinical trials.

Dr. Rosenberg is a member of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, North American Spine Society, American Academy of Pain Medicine, International Neuromodulation Society, North American Neuromodulation Society, AANS/CNS Joint Section on Pain, American Society of Stereotactic and Functional Neurosurgery, American Society for Clinical Oncology, Missouri State Medical Society, Metropolitan Medical Society, Kansas City Neurology/Neurosurgery Society and the Greater Kansas City Pain Society. He provides editorial support for Neuromodulation, the official journal of the North American Neuromodulation Society where he also serves on the Website and Education Committees. He is a member of the Scientific Review and Guidelines Committee for the American Academy of Pain Medicine and is an Executive Committee member of the AANS/CNS Joint Section on Pain.


Frederick L. Greene, MD

Clinical Professor of Surgery, University of North Carolina School of Medicine
Medical Director, Cancer Data Services, Levine Cancer Institute
Past Chair, Commission on Cancer & American Joint Committee on Cancer



Click to Read More

Frederick L. Greene, MD, FACS, received his medical school training at the University of Virginia where he was elected to membership into AOA. He completed a residency in surgery at Yale University School of Medicine. Dr. Greene was also an American Cancer Society Clinical Research Fellow at Yale. He was on active duty with the United States Navy and was surgeon on the USS Nimitz. He is currently the Chairman of the Department of General Surgery at Carolinas Medical Center in Charlotte, North Carolina, Director of the Surgical Residency Program at that institution and Clinical Professor of Surgery at the University of North Carolina School of Medicine.

Dr. Greene is an active clinician in the area of surgical oncology and has been involved in organizational work pertaining to cancer for a number of years. Dr. Greene is a Fellow of the American College of Surgeons and has served on the Board of Governors of that organization. Dr. Greene serves on the Commission on Cancer of the American College of Surgeons and served as the Chair of the Commission from 2004-2008. He has represented the American College of Surgeons on the American Joint Committee on Cancer (AJCC) and served as Chair of the AJCC from 2000-2006. Dr. Greene is the Editor of the 6th Edition of the AJCC Cancer Staging Manual.

Dr. Greene belongs to numerous surgical organizations including the Society of Surgical Oncology, the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the Southern Surgical Association and the American Surgical Association. Dr. Greene was a founding member of SAGES and served as its president in 1992-93.

Dr. Greene's publications have included approximately 160 papers, 30 book chapters and two textbooks relating to cancer surgery and, specifically, the use of laparoscopic surgery in the management of cancer patients. Dr. Greene serves as the Associate Editor of the Annals of Surgical Oncology and on numerous editorial boards including Surgical Endoscopy, Journal of Surgical Education, Journal of Surgical Oncology, World Journal of Surgery , American Surgeon, Journal of Clinical Oncology, Surgical Endoscopy, Laparoscopy and Percutaneous Techniques and is Editor of General Surgery News.


Howard G. Rosenthal, MD

Associate Professor of Orthopedic Surgery, The University of Kansas Health System, Sarcoma Center



Click to Read More

With more than 25 years of experience treating patients with tumors of the bone and soft tissues, Dr. Rosenthal is one of the foremost authorities in sarcoma surgery and treatment, having performed more than 4,500 limb salvage surgeries for musculoskeletal tumors since 1990. He is a fellow of the American College of Orthopaedic Surgeons and the American College of Surgeons. He has published numerous works and presented papers and lectures on limb preservation and sarcoma treatment. He serves on various committees of the Musculoskeletal Tumor Society, the International Society of Limb Salvage Surgeons, and the Connective Tissue Oncology Society.


Jay R. Harris, MD

Distinguished Professor, Department of Radiation Oncology, Dana-Farber Cancer Institute &
Brigham and Women's Hospital at Harvard Medical School
Past President, American Society for Radiology Oncology



Click to Read More

Dr. Harris is Distinguished Professor of the Department of Radiation Oncology at The Dana-Farber Cancer Institute and the Brigham and Women's Hospital at Harvard Medical School. He also serves as Residency Program Director for the Harvard Radiation Oncology Residency Program.

Dr. Harris' main research interest has been in the area of breast cancer, with a focus on establishing the most effective and safe radiation treatment for these patients. He helped pioneer the use of breast-conserving therapy for patients with early-stage breast cancer.

Dr. Harris has been an active member of several professional medical societies, including ASTRO where he served as president and chairman of the board of directors and the American Board of Radiology where he served as trustee.

Dr. Harris has published 100 articles and 150 peer-reviewed publications. He is the senior editor of Diseases of the Breast, now in its fourth edition.


Peter T. Scardino, MD

Chair of Surgery, Chief of Urologic Oncology, Head of the Prostate Cancer Research Program, Memorial Sloan Kettering Cancer Center
Professor of Urology, Weill Medical College of Cornell University



Click to Read More

EDUCATIONAL BACKGROUND
B.A.
Yale University, New Haven, CT
 
1967
M.D.
Duke University School of Medicine, Durham, NC
 
1971
PROFESSIONAL POSITIONS AND EMPLOYMENT
Post-doctoral training (include residency/fellowships)
Surgical Resident
Massachusetts General Hospital, Boston, Massachusetts
1971-1973
Clinical Associate, Surgery Branch
National Cancer Institute, National Institutes of Health, Bethesda, Maryland (fellowship in urologic oncology)
1973-1976
Urology Resident
UCLA, Los Angeles, California
1976-1979
Executive Development Program
School of Business Administration, University of Houston, Houston, Texas
1987
Chiefs of Service Program
Harvard University School of Public Health, Boston, Massachusetts
1996
Academic positions (teaching and research)
Instructor in Urology
UCLA
1978-1979
Assistant Professor of Urology
Baylor College of Medicine, Houston, Texas
1979-1982
Associate Professor of Urology
Baylor College of Medicine, Houston, Texas
1982-1986
Professor of Urology
Baylor College of Medicine, Houston, Texas
1986-1998
 
 
 
Russell and Mary Hugh Scott Professor and Chairman
Scott Department of Urology, Baylor College of Medicine, Houston, Texas
1989-1998
Distinguished Service Professor
Baylor College of Medicine, Houston, Texas
1995-1998
Professor of Urology
Weill Medical College of Cornell University, New York
1998-
Member
Memorial Sloan-Kettering Cancer Center (MSKCC), New York
1998-
Head, Prostate Cancer Program
MSKCC
1998-
Chief of the Urology Service
Murray F. Brennan Chair in Surgery, Department of Surgery, MSKCC
1998-1999
Chairman
Department of Urology and Alfred P. Sloan Chair, MSKCC
1999-2006
Member
Sloan-Kettering Institute for Cancer Research, New York
1999-
Florence and Theodore Baumritter/Enid Ancell Chair of Urologic Oncology
MSKCC
2000-
Professor
Department of Urology, College of Medicine, State University of New York Downstate Medical Center at Brooklyn, Brooklyn, New York
2000-
Acting Chief
Urology Service, Department of Surgery, MSKCC
2006-2008
David H. Koch Chair
Department of Surgery, MSKCC
2006-
Hospital positions (e.g., attending physician)
Senior Attending, Urology, and Chief of the Urology Service (1989-1998)
The Methodist Hospital, Houston, Texas
1979-1998
Active Staff, Urology, and Chief of the Urology Service (1989-1998)
Harris County Hospital District (Ben Taub General Hospital), Houston, Texas
1979-1998
Senior Attending Urologist
St. Luke’s Episcopal Hospital, Houston, Texas
1979-1998
Attending Surgeon
Memorial Hospital, New York, New York
1998-
Attending Urologist
New York Presbyterian Hospital-Cornell Medical Center, New York, New York
1998-
LICENSURE, BOARD CERTIFICATION, MALPRACTICE
Licensure
State
 
Date of issue
 
Massachusetts
 
04/73
 
Maryland
 
09/73
 
Texas
 
07/79
 
New York
 
05/98
 
 
Board Certification
National Board of Medical Examiners, 07/92
American Board of Urology, 1981
Malpractice insurance
Do you have Malpractice Insurance? Yes
Name of Provider: MSK Insurance Ltd.
Premiums Paid by: Memorial Sloan-Kettering Cancer Center
PROFESSIONAL MEMBERSHIPS (medical and scientific societies)
Member/Chair Section 6
Institute of Medicine, National Academy of Sciences (IOM)
1996-
Member
American Surgical Association (ASA)
2000-
Member
Clinical Society of Genitourinary Surgeons (CSGUS)
1991-
Member
American Association of Genitourinary Surgeons (AAGUS)
1988-
Member
American Urological Association (AUA)
1982-
Senior Member
Society of University Surgeons (SUS)
1982-
Fellow
American College of Surgeons (FACS)
1982-
Member
American Society of Clinical Oncology (ASCO)
1990-
Member
American Association for Cancer Research (AACR)
1996-
Member
Society of Urologic Oncology (SUO)
1990-
Member
The Society of Surgical Oncology, Inc. (SSO)
1997-
Honorary Member
Canadian Urological Association
2001-
Honorary Member
The Urological Society of Australasia
1998-
Member
Société Internationale d’Urologie (SIU)
1980-
Member
Urological Investigators Forum (UIF)
1980-
Member
Western Urological Forum (WUFER)
1981-
Member
Society for Basic Urologic Research (SBUR)
1987-
Member
Society of University Urologists (SUU)
1984-
Member
The New York Academy of Sciences (NYAS)
2000-
Member
The New York Academy of Medicine (NYAM)
2000-
Member
American Medical Association (AMA)
1981-
Honorary Member
 
Honorary Member
South CentralSection, American Urological Association (SCSAUA)
South Eastern Section, American Urological Association (SESAUA)
1981-1998
1990-
Member
 
Member
New York Section, American Urological Association (NYSAUA)
New York County Medical Society
1998-
2005-2006
Member
New York Clinical Society
2000-2002
Member
New York Medical and Surgical Society
2002-
Member
New York State Urological Society, Inc. (NYSUS)
2000-
HONORS AND AWARDS
Alpha Omega Alpha
1970
First Prize, Scientific Exhibit, American Urological Association
1981
Outstanding Faculty Member of the Year (one of six), Baylor College of Medicine
1985
George Slotkin Honorary Lecturer, New England and Northeastern Sections, AUA, Boston
1985
Leo Roon Visiting Professor, Harvard Medical School, Boston
1986
Gold Cystoscope Award, AUA (awarded to the individual who has contributed the most to urology within 10 years of his residency)
1989
Ballenger Memorial Lecturer and Appointed Honorary Member, Southeastern Section, AUA
1990
Named one of “The 400 Best Doctors in America” by Good Housekeeping magazine
1991
Director, Matsunaga-Conte Prostate Center Research Center, a designation by the National Cancer Institute of the Baylor College of Medicine SPORE (Specialized Program of Research Excellence), the first SPORE in prostate cancer awarded by the NCI
1992
Royal College of Surgeons Lecturer, Dublin, Ireland
1992
Listed in The Best Doctors in America, edited by Steven Naifeh and Gregory White Smith, Aiken: Woodward/White, Inc., p. 519
1992
Eugene Fuller Triennial Prostate Award of the AUA
1995
George Slothin Lecturer, Northeast Section, American Urological Association
1995
Named one of “The Best Medical Specialists” by Town & Country magazine
1995
Elected to the Institute of Medicine, National Academy of Sciences
1996
AUA Lecturer, European Association of Urology Biennial Meeting, Paris, France
1996
American Foundation for Urologic Disease Presidential Award
1996
Named one of “The Best Doctors in America” by American Health magazine
1996
British Journal of Urology Guest Lecturer, British Association of Urological Surgeons Annual Meeting
1997
Royal College Lecturer, Canadian Urological Association
1997
Kaneharu Suzuki Award, Suzuki Foundation for Urological Medicine, Japan
1998
Letter of Commendation from Richard D. Klausner, M.D. (Director, National Cancer Institute, National Institutes of Health) for work done on behalf of the National Cancer Institute’s Prostate Cancer Progress Review Group, Bethesda, Maryland
1999
Gordon Wilson Lecturer, American Clinical and Climatological Association
1999
William P. Burpeau Award, West Orange, New Jersey
1999
Distinguished Alumnus Award, Duke University Medical Center, Durham, North Carolina
1999
Named one of “Best Doctors In New York City” by New Yorkmagazine
2000-2003
Featured in TheNew York Times,The Wall Street Journal, USA Today, Washington Post, andThe New Yorker,People, Men’s Health, Forbes,andIn Touch magazines. TV and radio appearances: ABC World News Tonight, NBC Nightly News, NBC Today Show, WNBC Live At Five, WABC - Eyewitness News, WCBS Radio, Health Show - National Public Radioand CBS Network Radio
2000-2004
Keynote speaker, American Association for Cancer Research, New Discoveries in Prostate Cancer
2001
McPeak Lecturer, Society of the Memorial Sloan-Kettering Alumni
2001
Principal Investigator, SPORE in Prostate Cancer, Memorial Sloan-Kettering Cancer Center
2001
AUA Lecturer, Societe Internationale d’Urologie Meeting, Stockholm, Sweden
2002
Presidential Lecturer, Southeastern Section, American Urological Association
2003
Folke Edsmyr Memorial Lecturer and Award, Karolinska Institute, Stockholm, Sweden
2003
Society of Urologic Oncology Medal
2005
Henry Lichtwardt Lecturer, William Beaumont Hospital Graduation, Royal Oak, MI
2006
XXXI Sir Peter Freyer Memorial Lecture, Galway, Ireland
2006
Dr. G.M. Phadke Memorial Oration, Urological Society of India, Patna, India
2007
Whitmore Lecturer, Society of Urologic Oncology
2007
Named one of “The Best Doctors in America,” America’s Top Doctors, Castle Connolly Medical Ltd
Named one of “The Best Doctors in New York,” New York Magazine
Named one of “New York Super Doctors” by New York Times Magazine
Distinguished Contribution Award, American Urological Association
2008
 
2008
2008
2008
Barringer Medal, American Association of Genitourinary Surgeons
2009
INSTITUTIONAL/HOSPITAL AFFILIATION
Primary Hospital Affiliation
Memorial Hospital for Cancer and Allied Diseases
Other Hospital Affiliations
New York Presbyterian Hospital
Other Institutional Affiliations
Cornell University Medical Center
EMPLOYMENT STATUS
Name of Current Employer(s):
Memorial Sloan-Kettering Cancer Center
Employment Status (choose one):
Full-time
CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT
Postgraduate Education Courses Directed
Innovations in Urologic Practice, Postgraduate Course, Baylor College of Medicine
1985, 1987, 1996-1997
Ultrasonography in Urology, Postgraduate Education Course, American Urological Association
1987-1989
Transrectal Ultrasonography for Prostate Cancer, Annual Postgraduate Education Course, Baylor College of Medicine
1988-1989
Urologic Surgery, Post Graduate Course, American College of Surgeons
1990
Prostate Cancer, Annual Postgraduate Education Course, American Urological Association
1990-1997, 1999-2004
New Surgical Approaches in Prostate Cancer, New York Section of the American Urological Association, Barcelona, Spain
2002
Open and Laparoscopic Radical Prostatectomy, MSKCC, New York
2003
Treatment of High-Risk Prostate Cancer, Annual Postgraduate Education Course, American Urological Association
2009
Clinical Care
Outpatient office hours, 2 half days per week
1979-
Operating room, 2 days per week
Ward rounds, 5 days per week
1979-
1979-
Administrative Duties
Baylor College of Medicine
Admissions Committee
1981-1990
Institutional Review Board for Human Research
1983-1986
Chair, Admissions Committee
1987-1990
Director, Residency Training Program, Scott Department of Urology
1987-1996
Education 2001 Task Force
1988-1991
Executive Faculty Committee
1989-1998
Faculty Appointments and Promotions Committee
1990-1994
Research Advisory Committee
1991-1995
Curriculum Committee
1992-1997
Internal Advisory Committee on Center for Molecular Medicine
1992-1998
Search Committee, Director of Center for Gene Therapy
1995
Baylor MedCare Executive Committee and Board of Directors
1995-1998
Vision 2000 Steering Committee
1996
Strategic Planning Committee
1996
Academic Programs Committee
1997-1998
 
 
Other Committees
Committee on Review (appointments and promotions), Weill Medical College of Cornell University
2002-2005
Vice Chairman, Biomedical Ethics Committee, The Methodist Hospital
1986-1989
 
 
Memorial Hospital for Cancer and Allied Diseases
Surgical Executive Committee
1998-1999
Co-Chair, Genitourinary Cancer, Disease Management Team
1998-
Compliance Committee
2000-
Search Committee, Chief of Plastic Surgery
2001
Memorial Hospital Committee on Credentials, Appointments and Promotions (MHCCAP)
2004-
Committee on Appointments and Promotions (COAP)
2006-
Chair, Search Committee for Chair of Pathology
2008
Research
Discovery and validation of tissue markers of progression in prostate cancer
 
Development of new models of progression and decision-analysis using medical informatics
 
Longitudinal assessment of health related quality of life in men with localized prostate cancer
 
Optimizing surgical techniques for prostate cancer
 
Translational research in prostate cancer
 
 
 
Current Percent Effort (%)
Does the activity involve WMC students or researchers?
Does the activity involve MSK trainees or researchers?
Teaching/Mentoring
15
Y
Y
Clinical care
35
Y
Y
Administration
35
N
N
Research
15
N
Y
Total:
100%
---
---
RESEARCH SUPPORT
U01 CA84999-05 Molecular Classification of Prostate Cancer
NCI
$695,361
10/1/1999-03/31/2006
Principal Investigator: WL Gerald
Role: Co-Investigator
5%
Major goals: to define molecular profiles representative of androgen-independent prostate carcinoma by comprehensive, microarray-based gene expression analysis and comparison of androgen-dependent and —independent tumors, to develop robust molecular histopathologic methods to identify and quantitate androgen-dependent and —independent tumor cell subclones within primary human prostate carcinomas, and to analyze the relationship between molecular classification and clinical course of disease.
 
P50-CA 92629-06 SPORE in Prostate Cancer
NIH/NCI
$1,298,258
9/01/2001-8/31/2011
Principal Investigator: PT Scardino
30%
The major goals of this project are to continue the development of novel systemic therapy for prostate cancer. The development of better prognostic models of lethal variants of early stage prostate cancer and the characterization of important molecular pathways that lead to progression and metastases were designed to support our therapeutic objective by elucidation of specific targets within prostate cancer cells appropriate for mechanism-based therapy. Our central hypothesis has been that the molecular determinants of prostate cancer development and progression vary as the disease evolves.
 
Prostate Cancer Foundation (Award)
Prostate Cancer Research Program
$1,250,000
7/1/03-12/31/06
Principal Investigator: PT Scardino
% Effort: N/A
Major goal: To identify new tissue markers of progression and metastasis of human prostate cancer, analyze tissue specimens with a systems pathology, high throughput approach and characterize the long-term natural history of clinical localized prostate cancer
 
T32 CA082088-07 Urology Oncology Research Training Grant (first awarded in 1999)
NCI
$236,632
09/01/1999-02/28/2010
Principal Investigator: PT Scardino
15% effort
Major goal: to produce for the nation a larger cadre of superbly trained clinical scientists to become leaders in academic urologic oncology and who will be highly qualified to promote the revolution of medical care made possible by the developments in modern biomedical science.


Jimmie C. Holland, MD

Chairperson, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center



Click to Read More

Jimmie C. Holland, M.D., recognized internationally as the founder of the subspecialty of psycho-oncology, is Attending Psychiatrist and holds the first endowed chair in Psychiatric Oncology, the Wayne E. Chapman Chair at Memorial Sloan-Kettering Cancer Center. She is Professor of Psychiatry at Weill Medical College of Cornell University. She began the first fulltime psychiatric service in a cancer hospital in 1977 at Memorial Sloan-Kettering Cancer Center. From this base, the concept of psycho-oncology evolved to become a nationally recognized subspecialty of oncology. The Department of Psychiatry & Behavioral Sciences has trained over 300 psychologists and psychiatrists. Dr. Holland was PI of the first research grant in psycho-oncology which has continued uninterrupted for 26 years. Several key figures in psycho-oncology trained in the program: David Cella, Paul Jacobsen, Julia Rowland, Jamie Ostroff, Bill Redd, Bill Breitbart, as well as several in Europe.

Dr. Holland studied the prevalence and nature of psychological problems in patients with cancer in the 1970s and established the first committee studying psychological issues in a cooperative group, the Cancer Leukemia Group B. In the 1980s she became the Founding President of the International Psycho-oncology Society (1984) and of the American Psychosocial Oncology Society (1986). Dr. Holland has been senior editor of the Oxford University Press textbooks in psycho-oncology, first The Handbook of Psychooncology, (1989); Psycho-Oncology, (1998); and the 2nd Edition (2010). In 1992, she started the first international journal in the field, Psycho-Oncology, and continues as co-editor. Dr. Holland and Sheldon Lewis co-authored a book to help patients and their families cope with cancer, The Human Side of Cancer, (HarperCollins, 2000). Dr. Holland has chaired the National Comprehensive Cancer Network’s (NCCN) Panel on Management of Distress since its beginning in 1997. She served on the Institute of Medicine Multidisciplinary Committee which reported in 2007 that there is a new standard of quality cancer care today which demands that psychosocial interventions must be integrated into routine cancer care and clinical practice guidelines. Dr. Holland has received awards from the American Cancer Society, ASCO, AACR and the American Psychiatric Association. She was elected Member of the Institute of Medicine in 1995. She is married to Dr. James Holland, pioneer medical oncologist and Editor of the Holland-Frei textbook, Cancer Medicine. They have 6 children and 10 grandchildren.


George W. Sledge Jr., MD

Professor of Medicine, Chief, Division of Oncology, Stanford University



Click to Read More

George W. Sledge Jr., MD, is professor and chief of medical oncology at Stanford University Medical Center and most recently served as co-director of the breast cancer program at the Indiana University Cancer Center. He specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. He has published more than 280 articles in medical journals about breast cancer and chaired several nationwide clinical trials involving new breast cancer treatments. His work spans both laboratory and clinic.

Dr. Sledge serves as editor-in-chief of the journal Clinical Breast Cancer, and is past president of the American Society of Clinical Oncology. He served as chairman of the Breast Committee of the Eastern Cooperative Oncology Group from 2002 to 2009, where he played an important role in the development of several nationwide clinical trials. He has also served as chair of ASCO’s Education Committee, as a member of the Department of Defense Breast Cancer Research Program’s Integration Panel, as a member of the Food and Drug Administration’s Oncology Drug Advisory Committee, and currently as a member of the External Advisory Committee for The Cancer Genome Atlas project.

Dr. Sledge was awarded the Hope Funds for Cancer Research 2013 Award of “Excellence for Medicine.” He was also the recipient of the 2006 Komen Foundation Brinker Award for Scientific Distinction, the 2007 Breast Cancer Research Foundation's Jill Rose Award and the 2010 William L. McGuire Award from the San Antonio Breast Cancer Symposium.


Waun Ki Hong, MD

American Cancer Society Professor, Professor of Thoracic/Head and Neck Oncology, The University of Texas MD Anderson Cancer Center
Past President, American Association for Cancer Research
Past Member, Board of Directors, ASCO
Past Member, National Cancer Advisory Board, National Cancer Institute, NIH
Member, Institute of Medicine of the National Academy of Sciences



Click to Read More

Waun Ki Hong, M.D., is a leading authority on head, neck and lung cancers and one of the founders of cancer chemoprevention. Dr. Hong is Head of the Division of Cancer Medicine and Professor of Medicine at the University of Texas M.D. Anderson Cancer Center in Houston. He is an American Cancer Society Professor and holds the Samsung Distinguished University Chair in Cancer Medicine.

Beginning in the early 1980’s, Dr. Hong’s organ preservation research established new treatment standards that have enormously improved the quality of life for advanced laryngeal cancer patients. His seminal chemoprevention research has clearly shown that high-dose retinoids can reverse oral carcinogenesis—a proof of principle that has led to a new paradigm for cancer chemoprevention. He continues an active research program in chemoprevention with multiple clinical trials, and his molecularly-targeted approaches have the potential to significant improve the morbidity and mortality of head/neck cancer and lung cancers. Dr. Hong’s research offers the possibility that cancer can be indefinitely delayed and possibly prevented, thus offering patients many more healthy years of life.

Dr. Hong is the recipient of numerous national and international awards including AACR’s Joseph A. Burchenal and Rosenthal Foundation Awards, ASCO’s David Karnofsky Award, and a prestigious American Cancer Society Clinical Research Professorship. He also served as president of AACR in 2001. More recently, he received the AACR/Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research and is currently an elected member of the ASCO Board of Directors.

In addition to his research and clinical work, Dr. Hong has played a pivotal role in shaping public policy. He was a member of the Advisory Committee to the Director of the NCI from 1997-2002 and chaired the Prevention, Clinical, and Therapeutic Subcommittee for the Extramural Board of Scientific Advisors (BSA) of the NCI from 1996-2002, and has served as an advisor for numerous other national organizations. He has trained and nurtured hundreds of young physicians and scientists from around the world, and has played an active role in increasing international collaborations in cancer research.

President George W. Bush appointed Dr. Hong to the National Cancer Advisory Board (NCAB) in 2008. Dr. Hong will serve a six-year term through March 9, 2014. The function of the NCAB is to advise, assist and make recommendations to the secretary of the Department of Health and Human Services and the director of the National Cancer Institute. The NCAB may also make recommendations regarding support grants and cooperative agreements, technical and scientific peer review, and functions pertaining to the NCI.


Donald L. Trump, MD, FACP
CEO and Executive Director, Inova Dwight & Martha Schar Cancer Institute


Click to Read More

In addition to his new role at Inova, a five-hospital system in Northern Virginia, Dr. Trump maintains his appointment as professor of oncology at Roswell Park Cancer Institute. In both his role at Inova and his continued work with colleagues at Roswell, he oversees an expanding clinical research program focused on vitamin D-based prevention and therapeutics, funded by NCI and DOD. He holds European and U.S. patents for the use of vitamin D and vitamin D analogs in combination with high-dose chemotherapy. He continues an active practice in GU oncology with a particular focus on prostate cancer.
 
Dr. Trump earned his medical degree from The Johns Hopkins University School of Medicine in 1970. From 1970 to 1975, he completed an internship and residency training in Medicine and a fellowship in Oncology and served as Chief Resident in Internal Medicine at The Johns Hopkins Hospital. Dr. Trump is a Diplomate of the American Board of Internal Medicine, with Subspecialty Boards in Medical Oncology, and a Fellow of the American College of Physicians. 
 
Dr. Trump is past Secretary/Treasurer of the American Society of Clinical Oncology and is a member of many professional and scientific societies. He is a reviewer and/or member of the editorial board of prestigious journals, such as the New England Journal of Medicine, Journal of National Cancer Institute, Cancer, Journal of Urologic Oncology, Clinical Cancer Research, Cure, Oncology, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer Research, and Journal of Clinical Oncology. Dr. Trump has authored or co-authored more than 200 journal publications, book chapters and abstracts.


Mario E. Lacouture, MD

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center



Click to Read More

Dr. Lacouture is a board-certified dermatologist with special interest in dermatologic conditions that result from cancer treatments. His clinical career has been focused on the recognition and management of side effects affecting the skin, hair and nails of cancer patients and survivors, which can occur as a consequence of chemotherapy, radiation therapy and therapeutic transplants.

To ensure that dermatologic side effects do not affect quality of life and the consistent administration of anticancer therapies, Dr. Lacouture has founded the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary effort comprising patient care, education and research. This unique clinical program provides pretreatment counseling and preventive efforts to minimize the development of side effects as well as rapid attention to those patients who develop them. Close communication with treating oncologists ensures that interventions against side effects do not affect the effectiveness of cancer treatments to ensure the best dermatology-related quality of life and benefit from anticancer treatments.

Dr. Lacouture’s research focuses on major components of dermatologic side effects: the accurate description and severity grading; the effects on quality of life; the identification of factors that place individuals at higher risk; and the development of treatments. A basic tenet of this research is in exploring new skin treatments that do not affect the effectiveness of anticancer drugs. For example, topical medicines in the face or regional cooling of hands or feet are used to prevent or treat drug-induced side effects in these areas. Currently, dermatologic effects of cancer therapies in long-term cancer survivors are being investigated, the first step towards ensuring long-term skin health after cancer therapies.

In addition to his role in the treatment of dermatologic conditions in cancer patients and survivors, he is co-chair of the Skin Toxicity Study Group of the Multinational Association of Supportive Care in Cancer, an international organization devoted to the understanding of side effects in cancer patients.

________________________________________


Terry T. Tsue, MD, FACS

Vice President and Physician-in-Chief, The University of Kansas Cancer Center
Douglas A. Girod, MD, Endowed Professor of Head and Neck Surgical Oncology
Vice Chairman for Administrative Affairs, Department 
of Otolaryngology - Head and Neck Surgery,
The University of Kansas Health System



Click to Read More

Dr. Terry T. Tsue is currently physician-in-chief of the University of Kansas Cancer Center. He specializes in head and neck cancer, thyroid cancer and skull base surgery. He is also the senior examiner for the American Board of Otolaryngology in Houston and member of the ACGME Otolaryngology Residency Review Committee. He serves as chair of the RRC Milestones Committee.


LaSalle D. Leffall Jr., MD, FACS

Charles R. Drew Professor of Surgery, Howard University
Past Chair, President's Cancer Panel
Past President, American Cancer Society
Past President, Society of Surgical Oncology
Past President, American College of Surgeons
Past President, Society of Surgical Chairmen
Past President, Society of Black Academic Surgeons



Click to Read More

Dr. LaSalle D. Leffall Jr., is one of the leading authorities in breast cancer. He served as Chair of the Susan G Komen for the Cure organization and is past president of the American Cancer Society, Society of Surgical Oncology, American College of Surgeons, Society of Surgical Chairmen and Society of Black Academic Surgeons and past chair of the President’s Cancer Panel (for President Obama) and of C-Change (Along with former President George H. W. Bush). He was Professor and Chairman, Department of Surgery at Howard University for 25 years.

Global Medical Advisory Board Members:




Antonio Carlos Buzaid, MD (Brazil)

Chairman, Oncology Center of the Hospital São José da Beneficencia Portuguesa de São Paulo, Brazil


Click to Read More

Dr. Buzaid is an internist and medical oncologist in São Paulo, Brazil. He has served as the general director of the Oncology Center Hospital Sirio- Libanes in São Paulo as well as the medical director of the Melanoma and Skin Center at the University of Texas M. D. Anderson Cancer Center. He has also served as the medical director of the Melanoma Unit and co-director of the Lung Cancer Unit at Yale Comprehensive Cancer Center in New Haven, Conn. Dr. Buzaid is co-editor of the Manual de Oncologia do Brasil (10th edition), which has been translated into Spanish and English with more than 45,000 copies sold.


Gabriel N. Hortobagyi, MD, FACP (U.S.)

Professor of Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
Past President, American Society of Clinical Oncology


Click to Read More

Education
Universidad Nat’l of Columbia, MD Degree in Medicine, 1970.
St. Luke’s Hospital, Cleveland, OH, Resident Internal Medicine, 1971-74
U.T. MD Anderson Hospital, Houston, TX, Fellow Medical Oncology, 1976A. Positions and Honors Positions and Employment


1976-1977 Faculty Associate, Medical Breast Service, UTMDACC
1977-1980 Assistant Professor of Medicine, UTMDACC
1980-1985 Associate Professor of Medicine, UTMDACC
1980-1985 Director, Fellowship Program, Dept. Medical Oncology, UTMDACC
1984-1992 Chief, Breast Medical Oncology Service, UTMDACC
1985-Present Professor of Medicine, UTMDACC
1992-Present Chairman, Breast Medical Oncology, UTMDACC
1992-Present Director, Breast Cancer Research Program, UTMDACC
1998-Present Nellie B. Connally Chair in Breast Cancer, UTMDACC

Other Experience and Professional Memberships

1975 Diplomat, American Board of Internal Medicine
1977 Diplomat, American Board of Internal Medicine (Medical Oncology)
1993 - Present Corresponding Member - National Academy of Medicine, Argentina
1994 - Present Corresponding Member - National Academy of Medicine, Mexico
1995 Cino del Duca Award (Paris-France)
1997 Brinker International Award (Susan G. Komen Breast Cancer Foundation)
1999 Vermeille Medal of the City of Paris, France
2001 Chevalier de la Legion d’Honneur, Paris, France
2003 Horizon Scientific Achievement Award in Breast Cancer
2003 Glenn Robbins Award, New York Cancer Society
2004 Jeffrey A. Gottlieb Memorial Award
2004 - Present External Member - National Academy of Sciences, Hungary
2005 Laurea Honoris Causa – University of Modena and Reggio Emilia, Italy
2006 Pathfinder Award – American Society of Breast Disease
2006 - 2007 President, American Society of Clinical Oncology
2007 – Present Chair, Southwest Oncology Group Breast Committee

B. Selected peer-reviewed publications (in chronological order).
(Publications selected from over 500 peer-reviewed publications)

Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, and Champlin RE: Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. J Natl Cancer Inst 92(3):225-233, 2000.

Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Warner DL, Payne JY, Tucker SD, Bartolomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC: Cationic Liposome-Mediated Adenovirus Type 5 E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biological Effects: A Phase I Clinical Trial. J Clin Oncol 19:3422-3433, 2001.

Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer HM, Buchholz TA, and Hortobagyi GN: Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. J Clin Oncol 23(1):41-48, 2004.

Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN: Significantly Higher Pathological Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. J Clin Oncol 23(16):3676-3685, 2005

Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M: Biologic Markers in Axillary Node-Negative Breast Cancer: Differential Expression in Invasive Ductal Carcinoma versus Invasive Lobular Carcinoma. Clin Breast Cancer 7(5):396-400, 2006.

Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, and Hortobagyi GN: Neoadjuvant Therapy with Paclitaxel Followed by 5-Fuorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clin Cancer Res 13(1):228-233, 2007.

Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M: Kinetics of Serum HER-2/neu Changes in Patients with HER-2-Positive Primary Breast Cancer After Initiation of Primary Chemotherapy. Cancer 109(3):496-501, 2007. [Epub ahead of print on December 5, 2006].

Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN: Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients with Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol 2007. [Epub ahead of print on July 2, 2007].

Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G: Mammography Before Diagnosis Among Women Age 80 and Older with Breast Cancer. J Clin Oncol 2008. [Epub ahead of print on April 21, 2008] PMID: 18427152

Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS: Limits of Observational Data in Determining Outcomes from Cancer Therapy. Cancer 2008. [Epub ahead of print on April 21, 2008] PMID: 18428196

Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF and Hortobagyi GN: The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw in Cancer Patients Treated with Intravenous Bisphosphonates. J Bone Min Res 2008. [Epub ahead of print on February 5, 2008] PMID: 18435574

Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA: Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 2008. [Epub ahead of print on April 24, 2008] PMID: 18439768

Srokowski TP, Fang S, Duan Z, Buchholz TA, Hortobagyi GN, Goodwin JS, Giordano SH: Completion of Adjuvant Radiation Therapy Among Women With Breast Cancer. Cancer 2008. [Epub ahead of print on April 28, 2008] PMID: 18442124

Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans FW and Pusztai L: Evaluation of Biological Pathways Involved in Chemotherapy Response in Breast Cancer. Breast Cancer Res 2008. [Epub ahead of print on April 29, 2008] PMID: 18445275

Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; for the Inflammatory Breast Cancer Research Group: Prognostic Significance of HER-2 Status in Women with Inflammatory Breast Cancer. Cancer 112(9):1905-1911, 2008. [Epub ahead of print February 25, 2008]. PMID: 18300243

C. Research Support


1 P50 CA116199-01 Hortobagyi (PI)
9/23/2005 – 8/31/2010
NIH/NCI - UTMDACC SPORE in Breast Cancer
The goal of this project is to foster interactive, multi-specialty translational research in breast cancer diagnosis, prevention and treatment.
Role: PI

2P30 CA016672 28(PP-4) Hortobagyi (PI)
7/1/2003-6/30/2013
DHHS-NIH-NCI
Cancer Center Support (Core) Grant-Project 4-Breast Cancer Program
The major goal of this project is to establish the research infrastructure and organization for the Breast Cancer Research Program at The University of Texas M. D. Anderson Cancer Center.
Role: PI

Susan G. Komen Breast Cancer Foundation
7/1/2002 – 6/30/2010
Interdisciplinary Breast Cancer Fellowship Program
Hortobagyi (Program Director)
The major goal of this grant is to provide interdisciplinary training to physicians specializing in all aspects of the management of breast diseases.
Role: Program Director

ASCO Career Development Award Gonzalez-Angulo (PI)
7/1/2006 - 6/30/2009
The PI3K/PTEN/AKT Signal Transduction Cascade as a Predictor for Response to Therapy and Therapeutic Target in Breast Cancer
Goal: To study the role of the PI3K/PTEN/AKT Signal Transduction Cascade in breast cancer as a classifier, predictor of response, and target for preoperative therapy.
Role: Mentor

NCI: 1 U10 CA105409 Lippman (PI)
U10 Full Member Application Affiliated with SWOG
7/26/04-12/31/09
Goal: Development of Studies
Role: Co-Investigator

NCI: DHHS-NIH: 1 K23 CA12199401 (Gonzalez-Angulo (PI)
The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer
7/1/06-6/30/11
Goal: To study the relationship of P13K, PTEN, and SKT signal transduction in breast cancer.
Role: Consultant

The Breast Cancer Research Foundation: Breast Cancer-Targeted Therapy by Endostatin-Cytosine Deaminase Fusion Protein. (G.N. Hortobagyi, PI)
10/1/2008 – 9/30/2009
Role: PI

Past Support

DHHS–NIH-National Cancer Institute: 3 P50 CA116199-02S1 Bondy (Project PI)
(SPORE Supplement)
9/28/06 – 8/31/2008
Comparative Study of Breast Cancers and their Risk Factors Among Mexican Women in Mexico and the U.S.
Goal: Study the difference of risk factors between Mexican American women in the US and Mexico.
Role: SPORE PI

Entertainment Industry Foundation: EIF/WCRF Breast Cancer Biomarker Discovery Project.
P.I.: Leyland Hartwell
10/5/07 – 10/4/08
Role: Steering Committee Member: October 5, 2007 through October 4, 2008.

NCI: DHHS-NIH (1 K01 CA118174 01) Nahta (PI)
HER-2/IGF-1R Crosstalk and Herceptin Resistance
8/1/06 – 2/15/08
Goal: Study the relationship of HER-2/IGF-1R and Herceptin Resistance.
Role: Investigator

DAMD17-02-1-0694 01 Hortobagyi (PI)
9/1/2002 – 8/31/2007
USAMRMC-DOD Breast Cancer Research Program
Breast Cancer Center of Excellence: Development of Targeted Therapy Strategies for Breast Cancer.
The major goals of this project are to develop an interactive, multidisciplinary center that will combine expertise in molecular biology, novel animal models and clinical trials expertise to expedite the discovery and development of novel targeted therapies.
Role: PI

DAMD17-02-1-0456 1 Pusztai (PI)
4/012002 –4/31/2006
USAMRMC “The Role of Sigma Receptor in Breast Cancer”
The major role of this grant is to study and discover the role of sigma receptors in breast cancer.
Role: Co-Investigator

1RO1CA89608-O1A1 Bondy (PI)
7/1/2000 – 6/30/2006
NCI
Epidemiologic and Genetic Determinants of Breast Cancer Survival
The major goals of this project are to understand the influence of genetic and environmental influences on survival of patients with breast cancer.
Role: Co-Investigator


Eduardo Cazap, MD, PhD (Argentina)

Past President, Union for International Cancer Control (UICC-Geneva)
Founder and First President, Latin American & Caribbean Society of Medical Oncology (SLACOM)
Past President, Argentine Association of Clinical Oncology
 


Click to Read More

Eduardo Cazap MD, PhD is the founder and first President of the Latin American & Caribbean Society of Medical Oncology (SLACOM) since 2004 and in 2008 was elected by the General Assembly of the Union for International Cancer Control (UICC-Geneva) as President for the 2010-2012 period. In 2009 he was elected Board Member of the American Society of Clinical Oncology (ASCO-Alexandria), representing the international members. In September 2010 was nominated by the Argentinean government member of the Board of Directors of the newly created National Cancer Institute of Argentina.

After graduating in 1972 as a medical doctor from the University of Buenos Aires in his native city, Buenos Aires, Dr. Cazap was resident in Internal Medicine and then specialist in medical oncology at the Military Central Hospital and the Universidad del Salvador. He also completed fellowships at Strong Memorial Hospital, Rochester, New York and the Lombardi Cancer Center at Georgetown University, Washington, D.C. He was also fellow of the American Cancer Society in 1985.

Following his role as Principal Investigator of the Collaborative Cancer Research Treatment Program (PAHO-NCI) in 1984, he became Professor of Clinical Oncology at the Universidad del Salvador (1984-98) and then Professor of Medical Oncology at the Universidad Católica Argentina (1988-2000).

As well as having published over 170 papers, he has held many prominent positions in the medical arena, including Medical Director of the Instituto Dr. Estevez, Buenos Aires (1985-99) and representing Latin America at the European Society of Medical Oncology (ESMO), Lugano, Switzerland. He was President of the Argentine Association of Clinical Oncology (AAOC) in 1996-98 and 2000-02. In 2000, he was signatory of the Charter of Paris against Cancer. He is also a member of the Developing Countries Task Force for ESMO since 2002. Dr. Cazap was a member of the 2006 and 2008 UICC World Congress Program Planning Executive Committee and he is also an active member of ASCO, was Chairman of the International Affairs Committee, is member of the Cancer Prevention Committee and is member of the Board of Directors.

Dr. Cazap’s main areas of research and interest are cancer prevention, breast and cervical cancer, independent clinical research and global cancer control.

He has also performed several collaborative and advisory programs with World Health Organization (WHO-Geneva) and Pan American Health Organization (PAHO-Washington).

Dr. Cazap also serves as Chairman of the Executive Committee of the Breast Health Global Initiative (BHGI) which is co-sponsored by the Fred Hutchinson Cancer Research Center and Susan G. Komen for the Cure®. BHGI strives to develop and implement Guidelines for International Breast Health and Cancer Control for low- and middle-income countries.

One of Dr. Cazap’s most relevant ongoing projects is as Chair of the International Clinical Trials Working Group (ICTWG), a joint effort of ASCO and NCI-US, for the improvement of independent clinical cancer research at the international level.

He is also leading the International Cancer Prevention Stakeholders Group, under the umbrella of UICC and the support of ASCO. This initiative has been developed for international activities in cancer prevention gathering various organizations (UICC, ASCO, ESMO, AACR, ACS, WHO and others) in a common and coordinate strategy for the improvement of global cancer control.

Dr. Cazap was also elected President of the UICC World Cancer Congress that was held in Montreal, Canada, in 2012.


Yuko Kitagawa, MD, PhD, FACS (Japan)

Professor and Chairman, Department of Surgery, Keio University, School of Medicine
Director, Keio Cancer Center
Vice President, Keio University Hospital (Tokyo)


Click to Read More

Dr. Kitagawa is a surgical oncologist and clinical and translational researcher, primarily in the areas of gastrointestinal cancers. He is a chair of the Japan Esophageal Oncology Group and working as a principal investigator for several important nationwide clinical studies, including sentinel node mapping for gastric cancer and multimodal treatment for esophageal cancer. He is an editor-in-chief of Gastric Cancer, the official journal of the Japan Gastric Cancer Association and International Gastric Cancer Association. He is also serving as a chairman of the Japan chapter of the International Society of Surgery (ISS) / Société Internationale de Chirurgie (SIC).


Alexander M.M. Eggermont, MD, PhD (France)

General Director, Cancer Institut Gustave Roussy, Villejuif-Paris
President, European Academy of Cancer Sciences


Click to Read More

A melanoma specialist, Dr. Alexander Eggermont is the current president of the European Academy of Cancer Sciences and is past president of the European CanCer Organisation (ECCO) and the European Organisation for Research and Treatment of Cancer (EORTC). He is also a past member of the board of directors for the American Society of Clinical Oncology. Dr. Eggermont was a professor of surgical oncology at Erasmus University Medical Center in Rotterdam, Netherlands, and is the author or coauthor of more than 600 peer-reviewed publications, book chapters and monographs.


John F. Thompson, MD, FRACS, FACS (Australia)

Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia
Executive Director, Melanoma Institute Australia
Chairman, Australian & New Zealand Melanoma Trials Group
Past President, International Sentinel Node Society


Click to Read More

Dr John Thompson is Executive Director of Melanoma Institute Australia (formerly the Sydney Melanoma Unit), one of the largest melanoma treatment and research centres in the world. He is involved in many aspects of translational and clinical melanoma research, and has published widely on melanoma-related topics. He was chairman of the working party that produced the Australian and New Zealand Clinical Practice Guidelines for the Management of Cutaneous Melanoma. He is Chairman of the Australian and New Zealand Melanoma Trials Group and the Past-President of the International Sentinel Node Society.


Jaime G. de la Garza, MD (Mexico)

Director Emeritus, Instituto Nacional de Cancerologia, Mexico
Advisor, Consejo Mexicano de Oncologia
Former Director General, Instituto Nacional de Cancerologia, Mexico
Founder and Past President, Mexican Oncology Board


Click to Read More

  • BORN in Monterrey, N.L.Mexico, December 12, 1934.
  • STUDIES: Medical Doctor, Universidad Autónoma de Nuevo León-Monterrey,Mexico, 1952-1958;
  • Postgraduate in Internal Medicine and Medical Oncology in South Texas Medicine School; at San Antonio Texas. USA, 1959-1964;
  • Mayo Clinic, Rochester, Minnesota, 1965-1966.

DISTINCTIONS:

  • Educational Council For Foreign Medical Graduate Evanston Illinois, USA. 1962;
  • Senior Researcher "F" in the Institutos Nacionales de Salud,
  • Level II National Researcher of the Sistema Nacional de Investigadores of the CONACYT,
  • Doctor Honoris Causa granted by the Universidad Autónoma de Puebla,
  • Doctor in Medicine-Honoris Causa., Universidad Autónoma de Nuevo León.(Monterrey N.L.)
  • First representative of Latin America in the "Reunion Mundial de la Guerra contra el Cancer 2000" held in the Versailles Palace (Paris, France).
  • "11th.Cino del Duca Award,Achievement in Cancer Research" 14th. International Congress Anti-Cancer, feb. 4,2003. Versailles Palace (Paris, France).

PREVIOUS POSITIONS:

  • Former President of the Mexican Oncology Society(1980-81) and Founder and president of the Mexican Oncology Board(1998-2000),
  • Former General Director of the Instituto Nacional de Cancerología-Mexico(1993-2003),

CURRENT POSITIONS:

  • Executive Secretary Science Advisory Council for the Presidency of the Mexican Republic
  • Clinical Research Investigator at the Instituto Nacional de Cancerología-Mexico,
  • Member of the Academic Committee of the ICAT-PARIS Courses(1989-2008),
  • Advisor of the Consejo Mexicano de Oncología,
  • Member of the H. Administration Council of the Universidad Autónoma de Nuevo León,
  • Editorial Board of the Journal of the Instituto Nacional de Cancerología
  • Academic Reviewer of the Research Program of the Consejo Nacional de Ciencia y Tecnología, CONACYT,
  • Senior Researcher "F" in the Institutos Nacionales de Salud,
  • Level II National Researcher of the "Sistema Nacional de Investigadores of the CONACYT",
  • Reviewer Member of more than 10 International Journals,
  • Member of the International Affairs Committee of ASCO. 2004-2007. (Chair elect 2005) American Society of Clinical Oncology.(ASCO )
  • Member and founder of "Sociedad Lationamericana y del Caribe de Oncologia Medica" (SLACOM)
  • Miembro de ESMO Developing Countries Task Force. 2005.

SCIENTIFIC PRODUCTION:

  • Author of more than 160 works in national and international arbitrated journals, chapters in book;
  • Lecturer of more than 1000 national and international lectures, among others.

MEDICAL SOCIETIES:

  • Academia Nacional de Medicina,Mexico,
  • Academia Mexicana de Cirugía,
  • Academia Mexicana de Ciencias
  • American Society of Clinical Oncology;(ASCO)
  • Alumni Association Mayo Graduate School of Medicine, University of Minnesota, USA
  • Soc.Latinoamericana y del Caribe de Oncologia Medica(SLACOM)
  • European Society Medical Oncology(ESMO) among others.


Yi-Long Wu, MD (China)

Vice President, Guangdong General Hospital
Director, Guangdong Lung Cancer Institute
President, Chinese Society of Clinical Oncology


Click to Read More

Dr.Wu graduated from Sun Yat-sen University of Medical Sciences in 1982 and completed his thoracic surgery training in Germany in 1989. His main research interests include multidisciplinary synthetic therapy on lung cancer and evidence-based medicine in oncology. As vice-president of the Guangdong General Hospital & Guangdong Academy of Medical Sciences and a director of Guangdong Lung Cancer Institute, he also serves as president of the Chinese Society of Clinical Oncology(CSCO) and the president of the Chinese Thoracic Oncology Group (C-TONG).

Dr. Wu is leading the Chinese lung cancer field and has been a principle investigator or co-principle investigator in more than 90 multicenter clinical trials.A contributor to 20 books oncancer, he has also published more than 300 articles in peer-reviewed journals. He also serves on the editorial boards of Cancer Letters, Annals of Surgical Oncology, Lung Cancer Management, International Journal of Biological Marker and General Thoracic and Cardiovascular Surgery. He is editor-in-chief of Journal of Evidence-based Medicine, Journal of Thoracic Oncology (Chinese Edition) and Oncologist (Chinese Edition).

Dr. Wu also serves as president of the International Chinese Society of Thoracic Surgery (ICSTS) and is a Fellow of the American College of Surgeons.

 

Patient Advisory Board Members:




Alan J. Balch, PhD

CEO, National Patient Advocate Foundation &
Patient Advocate Foundation


Click to Read More

Now serving as CEO of NPAF and PAF, Dr. Alan Balch most recently was vice president of the Preventive Health Partnership, a collaboration between the American Cancer Society, the American Diabetes Association, and the American Heart Association. He is also the past executive director of Friends of Cancer Research. Balch volunteers as a member of the board of directors for the Center for a New American Dream and the Colorectal Cancer Coalition. He holds a doctorate in environmental studies and a master’s in environmental sciences.


Linda House, RN, BSN, MSM

President, Cancer Support Community


Click to Read More

Now serving as president of Cancer Support Community, Linda House joined the organization in February 2012 as executive vice president of external affairs where she oversaw the development, communications and public policy efforts of the national organization. Linda joined CSC with around 30 years of experience working in the cancer care environment, 17 years being direct patient care in the acute and hospice care setting.

Immediately prior to joining CSC, Linda served as executive director of St. Vincent Cancer Care in Indianapolis where she led a team of individuals to provide care across the cancer continuum. Prior to that, Linda was senior director of advocacy and professional relations for Lilly Oncology working with patient and professional organizations on programs and broad issues related to cancer care.

Linda has served in a variety of roles in the national cancer community including Board Chair for Y-ME National Breast Cancer Organization, C-Change Together's Value of Cancer Care and Workforce panels, the National Cancer Institute Director's Consumer Liaison Group, the Education Network to Advance Cancer Clinical Trials Collaborative expert panel. Linda is also an active volunteer with a number of organizations in her local community.


Diane S. Blum, MSW

Past CEO, Lymphoma Research Foundation


Click to Read More

Diane S. Blum is chief executive officer of the Lymphoma Research Foundation, the nation's largest voluntary health organization devoted exclusively to funding lymphoma research and providing patients and health care professionals with critical information on the disease. She also served for twenty years as the Executive Director of CancerCare and recently served as Editor-in-Chief of ASCO’s cancer.net. Blum is a founder of National Breast Cancer Awareness Month and Co founder of the National Alliance of Breast Cancer Organizations. Most recently, she received ASCO's 2009 Partners in Progress award which honors patient advocates whose work has increased public awareness about cancer and its causes, cures and treatment.


Paula T. Rieger, MSN, RN, CAE, FAAN

Past President, Oncology Nursing Society


Click to Read More

Paula Rieger, MSN, RN, CAE, FAAN, served as the chief executive officer of the Oncology Nursing Society from 2007 to 2014. Prior to that, she served as the director of international affairs for the American Society of Clinical Oncology. She worked as a nurse at The University of Texas MD Anderson Cancer Center in Houston for 23 years, focused primarily in the field of medical oncology with an expertise in both biological therapies and cancer genetics.

Rieger received her Master of Science in Nursing from The University of Texas Health Science Center in Houston after receiving her Bachelor of Science in Nursing degree from the University of California, Los Angeles in 1978. Rieger also holds a Bachelor of Science in Biology from U.C. Davis and has completed studies as a nurse practitioner at The University of Texas Health Science Center at Houston. She achieved her certification as a certified association executive (CAE) from the American Society of Association Executives (ASAE) in 2010.

She has been active at both the local and national levels of the Oncology Nursing Society. She served on the ONS Board of Directors as secretary and on the Oncology Nursing Foundation Board of Directors from 1995-1998. She completed a two-year term as president of the Oncology Nursing Society in April 2002 and a two-year term as immediate past-president in 2004, where she served on the Nominating Committee. She also served as an associate editor for “Oncology Nursing Forum” and was a co-editor of the Leadership & Professional Development column. She served as the lead coordinator for the coordinating team of the Nursing Organization Alliance (NOA) from 2009-2010. Following her retirement in 2014, she was recognized by NOA as a nursing legend for “impact on the nursing profession and the legacy she left behind.”

She has maintained continuous support of the nursing profession through publications, contributions as a research collaborator, and more than 200 presentations at scientific and professional meetings on biotherapy, cancer genetics, symptom management and other cancer-related topics. She has edited four books on the subject of biotherapy and served as a consultant in the production of numerous educational videotapes for both patients and health care professionals. In 1992, she was awarded the Schering/ONS Excellence in Biotherapy Award and in 1994 was a co-recipient of the ONS/CHIRON Therapeutics/Susan Baird Oncology Excellence in Writing Award. In 1993, she received the International Patient Education Council’s Outstanding Patient Educator Award. In 1997, Rieger was awarded an Oncology Nursing Foundation grant for “Nurses’ Knowledge and Attitudes Regarding Genetics and Genetic Testing.” In 1997, she was inducted as a fellow in the American Academy of Nursing. In 1999, she was awarded the Oncology Nursing Society/Ortho Biotech Inc. FIRE Excellence Award for recognition of outstanding achievements in the field of fatigue management. In 2014, she was chosen as the UCLA School of Nursing Distinguished Alumni.


Sam Donaldson

ABC Newscaster


Click to Read More

Sam Donaldson is an internationally known broadcast journalist and a 42-year veteran of ABC News for whom he served two appointments as chief White House correspondent covering Presidents Carter, Reagan and Clinton. In 1998 Mr. Donaldson received the prestigious Broadcaster of the Year Award from the National Press Foundation. The Washington Journalism Review named him the Best Television Correspondent in the Business in 1986, 1987, 1988 and 1989. Mr. Donaldson has won many other awards, among them four Emmy Awards and three Peabody Awards. His 1987 autobiography, "Hold On, Mr. President," was an international bestseller. Currently, Donaldson is appearing on ABC News Now, the ABC News digital network.


Lillie D. Shockney, RN, BS, MAS, ONN-CG

University Distinguished Service Professor of Breast Cancer
Director, Johns Hopkins Avon Foundation Breast Center
Director, Johns Hopkins Survivorship Programs


Click to Read More

Lillie D. Shockney, is an active clinical researcher with a focus on quality of life issues for survivors. She has written eight books and many articles on the subject of breast cancer. She is the co-founder and vice president of "Mothers Supporting Daughters with Breast Cancer." She serves as Ask an Expert for several breast cancer websites including Yahoo.com and the Johns Hopkins Breast Center's website, and she chairs the National Consortium of Breast Centers QI Task Force.


Brian Garofalo

President, Patient Alliances, LLC


Click to Read More

Brian Garofalo has over twenty years of management experience with three major pharmaceutical and bio-pharmaceutical companies. He has been an effective liaison for his industry and patient communities in the disease areas of Cancer, HIV/AIDS, Diabetes and Cardiovascular. Garofalo's advocacy career has focused mainly on ensuring patients and physicians have the ability to maintain access to innovative therapies. He himself is a cancer survivor and is widely sought for his experience and passion for the patient – understanding that whatever the issue may be, solutions are more plausible if a patient-centric approach is maintained. He has started his own consulting company, Patient Alliances, LLC - providing strategic healthcare alliances and solutions for a number of diversified clients.


Doug Ulman

CEO, Pelotonia


Click to Read More

Doug Ulman is a three-time cancer survivor and national cancer survivorship advocate. Formerly the president and chief executive officer of the LIVESTRONG Foundation, he also founded the Ulman Cancer Fund for Young Adults, a nonprofit organization to provide support, education and resources to young adults, their families and friends affected by cancer. As CEO of Pelotonia, he oversees the group's objective to fund life-saving cancer research through its three-day experience that includes a weekend of cycling, entertainment and volunteerism. Pelotonia is able to direct 100 percent of every rider-raised dollar to cancer research at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. Ulman also serves as chairman of the National Cancer Institute Director’s Consumer Liaison Group and sits on the Google Health Advisory Board. He is a member of the American Society of Clinical Oncology and co-founder of the LIVESTRONG Young Adult Alliance.


Lisa Greaves

Division Director, Educational Meetings, American Society of Clinical Oncology


Click to Read More

Lisa Greaves is the Division Director of Educational Meetings at the American Society of Clinical Oncology. She is a long-term survivor of breast cancer who connects with newly diagnosed patients through community organizations and speaking at cancer awareness events. Greaves is a graduate of the National Breast Cancer Coalition Fund’s Project LEAD Institute. She serves on the Board of Directors of the Breast Cancer Care Foundation, a DC-based nonprofit that supports residents who are underserved, uninsured, or otherwise have insufficient financial resources for breast health care. Greaves has explored her own cancer journey through photography and poetry.


Armin D. Weinberg, PhD

Clinical Professor, Baylor College of Medicine
Adjunct Professor, Rice University
Adjunct Professor, TAMU School of Public Health
Co-Founder, Intercultural Cancer Council


Click to Read More

Dr. Weinberg is CEO of Life Beyond Cancer Foundation and Clinical Professor of Medicine at Baylor College of Medicine. The Life Beyond Cancer Foundation, a 501(c)(3) public foundation dedicated to improving the lives of cancer patients and their families on their journey to a life beyond cancer through it’s national Providers for Survivors Network.  He was the Principal Investigator of the Eliminating Disparities in Clinical Trials Project (EDICT), a research study designed to address the problems and find workable solutions to recruiting and retaining populations that are underrepresented in clinical trials such as low income, elderly, racial-ethnic minorities or those who live in rural areas.  Dr. Weinberg began his career at Baylor in 1975 as Director of the Education Division of the DeBakey Heart Center.  Recognizing that the community models he had developed could be applied to other chronic diseases, Dr. Weinberg established the Chronic Disease Research Center (CDRC) in 1987. By broadening his work to include other chronic diseases including cancer Dr. Weinberg’s efforts focused on translating our discovers in prevention, screening, and control activities to state and national initiatives.  Relatedly, Dr. Weinberg has spearheaded effort international partnerships with Kiev – Ukraine, Semipalatinsk - Kazakhstan, Baku – Azerbaijan, Sakhalin - Russia, sponsored by the American International Health Alliance.  He was also a founding member of the International Consortium for Research on the Health Effects of Radiation, founded in response to the Chernobyl nuclear accident.Dr. Weinberg currently serves as Chair of the Cancer Alliance of Texas (CAT), member of the Physician Oncology Program at the Texas Medical Association, Redes En Acción National Center Steering Committee (NCSC), Executive Committee of the National Hispanic Life Science Society, board member of Texas Life Science Foundation, The Schull Institute and Volunteer Houston, past member of the board of C-Change: Collaborating to Conquer Cancer, The National Association of Social Worker Foundation, The Texas Hadassah Medical Research Foundation and was the co-founding Chair of the Intercultural Cancer Council (ICC). This national consortium was an outgrowth of the Biennial Symposia on Minorities, the Medically Underserved & Cancer.



Register Now! Sign Up For Our Free E-Newletter!

Read Inspiring Cancer Survivor Stories

Order Your Guides Here